Alexandra Dreyzin
Overview
Explore the profile of Alexandra Dreyzin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dreyzin A, Shao L, Cai Y, Lee Han K, Prochazkova M, Gertz M, et al.
Mol Ther
. 2025 Mar;
PMID: 40087865
Although CAR T-cell therapy is increasingly used to treat relapsed B-cell acute lymphoblastic leukemia (ALL), 20-30% of patients do not respond, and few clinical predictors of response have been established,...
2.
Traynor R, Vignola I, Sarkar S, Prochazkova M, Cai Y, Shi R, et al.
Cytotherapy
. 2024 Dec;
27(3):400-409.
PMID: 39652017
Background: Chimeric antigen receptor T (CAR-T) cells have significantly advanced the treatment of cancers such as leukemia and lymphoma. Traditionally, T cells are collected from patients through leukapheresis, an expensive...
3.
Dreyzin A, Rankin A, Luciani K, Gavrilova T, Shah N
Expert Rev Clin Immunol
. 2024 May;
20(7):745-763.
PMID: 38739466
Introduction: While CAR T-cell therapy has led to remarkable responses in relapsed B-cell hematologic malignancies, only 50% of patients ultimately have a complete, sustained response. Understanding the mechanisms of resistance...
4.
Prochazkova M, Dreyzin A, Shao L, Garces P, Cai Y, Shi R, et al.
J Transl Med
. 2024 Apr;
22(1):384.
PMID: 38659083
Background: Chimeric antigen receptor (CAR) T-cells have demonstrated significant efficacy in targeting hematological malignancies, and their use continues to expand. Despite substantial efforts spent on the optimization of protocols for...
5.
Mamo T, Dreyzin A, Stroncek D, McKenna D
Clin Chem
. 2024 Jan;
70(1):116-127.
PMID: 38175598
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of hematologic malignancies and holds promise for solid tumors. While responses to CAR T-cell therapy have surpassed other available options...
6.
Dreyzin A, Cheng J, Leitenberg D, Diab Y
Pediatr Blood Cancer
. 2023 Mar;
70(7):e30304.
PMID: 36975155
No abstract available.
7.
McNerney K, Si Lim S, Ishikawa K, Dreyzin A, Vatsayan A, Chen J, et al.
Blood Adv
. 2023 Mar;
7(12):2758-2771.
PMID: 36857419
Chimeric antigen receptor-associated hemophagocytic lymphohistiocytosis (HLH)-like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case...
8.
Dreyzin A, Panch S, Shalabi H, Yates B, Highfill S, Jin P, et al.
Mol Ther Methods Clin Dev
. 2023 Jan;
28:51-61.
PMID: 36620075
Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy...
9.
Dreyzin A, Jacobsohn D, Angiolillo A, Wistinghausen B, Schore R, Perez E, et al.
Pediatr Hematol Oncol
. 2021 Oct;
39(4):370-378.
PMID: 34672243
No abstract available.
10.
Dreyzin A, Mccormick M, Zullo J, Shah S, Kalpatthi R
Acta Paediatr
. 2020 Sep;
110(2):624-630.
PMID: 32984994
Aim: We aimed to describe changes in invasive pneumococcal disease (IPD) hospitalisations after introduction of the pneumococcal conjugate vaccine (PCV13). Methods: This was a retrospective analysis of the Pediatric Health...